Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022
James Brady joined the Board as Non-Executive Director
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.